A New Era in Prostate Cancer Treatment? Understanding DNA Repair Deficiencies and the Therapeutic Rationale for PARP Inhibition

In this online educational program expert faculty explore PARP inhibitors in advanced prostate cancer treatment including an overview of DNA repair deficiencies in prostate cancer a review of available clinical data how these agents may affect management strategies for patients in the near future and insights into practical challenges associated with genetic testing.

Share

Program Content

Activities

DNA Repair Deficiency in PCa
Overview of DNA Repair Deficiency in Advanced Prostate Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 14, 2018

Expires: February 13, 2019

Genetic Testing in PCa
The Intersection of Germline and Somatic Genetic Testing in Advanced Prostate Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 14, 2018

Expires: February 13, 2019

PARPi in Advanced PCa
DNA Repair Defects as a Therapeutic Target in Advanced Prostate Cancer: The Role of PARP Inhibitors
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 14, 2018

Expires: February 13, 2019

Activities

PARPi in Prostate Cancer
A New Era in Prostate Cancer Treatment? Understanding DNA Repair Deficiencies and the Therapeutic Rationale for PARP Inhibition
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: March 06, 2018

Expires: March 05, 2019

Faculty

cover img faculity

Emmanuel S. Antonarakis, MBBCh

Professor
Department of Oncology and Urology
Johns Hopkins University
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

cover img faculity

Heather H. Cheng, MD, PhD

Associate Professor
Department of Medicine (Hematology and Oncology)
University of Washington
Division of Clinical Research
Fred Hutchinson Cancer Center
Seattle, Washington

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca